Enforcement Report - Week of April 3, 2024
Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of August 31, 2022
Enforcement Report - Week of August 3, 2022
Paris - A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects.
Unichem Laboratories yesterday said it has received approval from the US health regulator to market its generic version of Divalproex Sodium extended-release tablets used for treatment of bipolar disorder and migraine.
PARIS, Jan 5 (Reuters) - A French court ruled on Wednesday that families of victims of Depakine, an epilepsy drug that caused birth defects and learning difficulties when taken during pregnancy, could join a class action lawsuit against drugmaker Sanofi.
Intra-Cellular Therapies, a biopharmaceutical company focused on the ndevelopment and commercialisation of therapeutics for central nervous nsystem (CNS) disorders, have announced the FDA approval of CAPLYTA for nthe treatment of depressive episodes associated with bipolar I or II ndisorder in adults. The treatment has been approved as monotherapy and nas adjunctive therapy with lithium or valproate.
Enforcement Report - Week of October 6, 2021
Enforcement Report - Week of September 29, 2021